EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment method using a cGMP-Specific PDE inhibitor



Treatment method using a cGMP-Specific PDE inhibitor



Official Gazette of the United States Patent & Trademark Office Patents 1245(3), Apr 17



A compound of formula ##STR1## and salts and solvates thereof, wherein R0, R1, and R2 are defined in the specification. A compound of the present invention is a potent and selective inhibitor of cGMP-specific PDE and has utility in a variety of therapeutic areas where such inhibition is beneficial.

(PDF 0-2 workdays service: $29.90)

Accession: 035980288

Download citation: RISBibTeXText



Related references

Method for treating patients with acne by administering a CGMP-specific PDE inhibitor. Official Gazette of the United States Patent & Trademark Office Patents 1242(4), Jan 23, 2001

Characterization and effects of methyl-2- -1,2-dihydro-1-oxo-7- -4- -3-isoquinoline carboxylate sulfate , a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase. Biochemical Pharmacology 60(9): 1333-1341, 1 November, 2000

Increased expression of the cGMP-inhibited cAMP-specific and cGMP binding cGMP-specific phosphodiesterases in models of pulmonary hypertension. British Journal of Pharmacology 137(8): 1187-1194, December, 2002

Characterization and effects of methyl-2- (4-aminophenyl)-1, 2-dihydro-1-oxo-7- (2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochemical Pharmacology 60(9): 1333-1341, 2000

Prolonged treatment of porcine pulmonary artery with nitric oxide decreases cGMP sensitivity and cGMP-dependent protein kinase specific activity. American Journal of Physiology. Lung Cellular and Molecular Physiology 296(1): L121-L129, 2008

The GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) is a sensor and a sink for cGMP. Biochemistry 47(11): 3534-3543, 2008

Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms. Molecular Pharmacology 77(4): 670-677, 2010

Studies of the molecular mechanism of discrimination between cGMP and cAMP in the allosteric sites of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). Journal of Biological Chemistry 274(41): 29038-29041, 1999

The gamma subunit of the rod photoreceptor cGMP phosphodiesterase can modulate the proteolysis of two cGMP binding cGMP-specific phosphodiesterases (PDE6 and PDE5) by caspase-3. Cellular Signalling 13(10): 735-741, 2001

Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP. Biochemistry (American Chemical Society) 41(30): 72-9, 2002

Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity. Biochemistry 37(12): 4200-4205, 1998

Individual cerebellar Purkinje cells express different cGMP phosphodiesterases In vivo phosphorylation of cGMP-specific PDE as an indicator of cGMP-dependent protein kinase activation. Journal of Neuroscience 23(16): 6452-6459, July 23, 2003

Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. Journal of Neuroscience 23(16): 6452-6459, 2003